Online Exclusive

  • Alemtuzumab Improves Survival in Patients With Chronic Lymphocytic Leukemia Friday, January 20th, 2017 | , ,

    An open-label, phase II study published in the British Journal of Haematology found that, in patients with chronic lymphocytic leukemia (CLL) who achieved negative minimal residual disease (MRD) status with chemotherapy, consolidation therapy with alemtuzumab improved progression-free survival (PFS) and overall survival (OS). The results confirm remission duration and survival in patients with CLL are […]

  • Pediatric Patients With Down Syndrome and ALL Can Be Safely, Effectively Treated With Standard Regimens Thursday, January 19th, 2017 | , ,

    Treatment modifications and dose reductions are common strategies in managing pediatric patients with Down syndrome and acute lymphocytic leukemia (ALL). According to results from a study presented at the 2016 ASH Annual Meeting by Uma H. Athale, MD, though, ALL patients with Down syndrome have comparable survival outcomes and toxicity profiles to ALL patients without […]

  • Researchers Develop Nanoscale Ultrasound Procedure for Cancer Research Wednesday, January 18th, 2017 | , ,

    Researchers at the University of Nottingham in the United Kingdom have developed an ultrasound imaging technique that uses sound rather than light to view the interior of cells. Compared with conventional optical microscopy, this technique allows researchers to image smaller cells and get higher-resolution images without damaging the cells. Fernando Pérez-Cota, PhD, and authors, who […]

  • Admission to ICU Associated With Increased Mortality and Comorbidities for Patients With AML Tuesday, January 17th, 2017 | , ,

    A study published in JAMA Oncology found that patients with acute myeloid leukemia (AML) who were admitted to the intensive care unit (ICU) had greater in-hospital mortality than those who were not (43.1%; n= 4857 vs. 9.3%; n=2,959; p values not reported), and defined risk factors for ICU admission and in-hospital mortality. Anna B. Halpern, […]

  • Researchers Link Obesity-Associated Protein With AML Monday, January 16th, 2017 | , ,

    Preclinical research indicates that the fat mass- and obesity-associated protein FTO (an N6-methyladenosine [m6A]) is involved in the development of acute myeloid leukemia (AML) and may affect response to treatment. FTO regulates the expression of a set of genes through a mechanism involving RNA modification, which increases the proliferation of leukemia cells and inhibits response […]

1 of 34
back to top